• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    USANA Health Sciences Reports First Quarter 2026 Results

    5/5/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    Company Continues to Make Significant Progress on Transformation to Becoming a Leading Omnichannel Health and Wellness Platform

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended April 4, 2026.

    Key Financial Results

    First Quarter 2026 vs. First Quarter 2025

    • Net sales of $250 million versus $250 million.
    • Net earnings of $7.5 million versus $9.4 million.
    • Diluted EPS of $0.41 as compared with $0.49.
    • Adjusted diluted EPS(1) of $0.61 as compared with $0.73.
    • Adjusted EBITDA(2) of $28.4 million versus $29.8 million.
    • Core Nutritional Active Customers of 404,000 versus 459,000.
    • Hiya Active Monthly Subscribers of 186,000 versus 224,000.
    • Company reiterates fiscal 2026 guidance.

    Q1 2026 Consolidated Performance

     

    Q1 2026

    Year-Over-Year

    Sequentially

    Net Sales

    $250 million

    Flat (+$8 million or +3% FX impact)

    +11%

    Net Earnings

    $7.5 million

    -20%

    N/A

    Diluted EPS

    $0.41

    -16%

    N/A

    Adjusted Diluted EPS(1)

    $0.61

    -16%

    +2%

    Adjusted EBITDA(2)

    $28.4 million

    -5%

    +4%

    Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.

    "Our first quarter 2026 results reflect USANA's continued evolution from a single-channel direct sales business to a diversified, omnichannel health and wellness enterprise," said Kevin Guest, Chairman and Chief Executive Officer. "Our omnichannel platform is intended to provide multiple growth engines, and early progress across our three segments reinforces confidence that our strategy will deliver sustained incremental value over time. The Core Nutritional business delivered solid sequential improvement during the quarter, driven by growth in total active customers in China in addition to continued focus on accelerating our new product launch initiatives. Meanwhile, Hiya established the operational foundation for a meaningfully stronger second half of the year and Rise Wellness generated triple-digit growth as Protein Pop hit Costco shelves nationwide.

    "As we look ahead, the investments we are making today in product innovation, brand building, channel expansion, and technology modernization reinforce confidence in our strategic direction. These investments position us to compete effectively across the full spectrum of health-conscious consumer shopping preferences. We are committed to advancing our omnichannel strategy with urgency and discipline."

    Q1 2026 Segment Results

    Core Nutritional

    Core Nutritional

     

    Q1 2026

    Year-Over-Year

    Sequentially

    Net Sales

    $204 million

    -3%

    +7%

    Active Customers

    404,000

    -12%

    +4%

    Asia Pacific Region

     

    Q1 2026

    Year-Over-

    Year

    Year-Over-Year

    (Constant Currency)

    Sequentially

    Net Sales

    $169 million

    -2%

    -6%

    +12%

    Active Customers

    326,000

    -13%

    N/A

    +7%

    Asia Pacific Sub-Regions

     

     

    Q1 2026

    Year-Over-

    Year

    Year-Over-Year

    (Constant Currency)

    Sequentially

    Greater China

    Net Sales

    $123 million

    +4%

    Flat

    +23%

    Active

    235,000

    -7%

    N/A

    +13%

    Customers

    North Asia

    Net Sales

    $15 million

    -19%

    -18%

    -9%

    Active

    32,000

    -29%

    N/A

    -9%

    Customers

    Southeast Asia Pacific

    Net Sales

    $31 million

    -14%

    -20%

    -10%

    Active

    59,000

    -21%

    N/A

    -6%

    Customers

    Americas and Europe Region

     

    Q1 2026

    Year-Over-

    Year

    Year-Over-Year

    (Constant Currency)

    Sequentially

    Net Sales

    $35 million

    -6%

    -10%

    -13%

    Active Customers

    78,000

    -8%

    N/A

    -4%

    Hiya Health

     

    Q1 2026

    Year-Over-Year

    Sequentially

    Net Sales

    $32 million

    -13%

    +7%

    Active Monthly Subscribers

    186,000

    -17%

    +2%

    Rise Wellness

     

    Q1 2026

    Year-Over-Year

    Sequentially

    Net Sales

    $14 million

    +741%

    +143%

    Balance Sheet

    The Company ended the quarter with $163 million in cash and cash equivalents and $14 million of debt. As of April 4, 2026, inventory totaled $99 million, a decrease of approximately $8 million, or -7% compared to balances at year-end 2025. This decrease was driven by strong performance by Rise Wellness, particularly from the fulfillment of orders with key retailers.

    The Company did not repurchase any shares during the quarter and has approximately $34 million remaining under the current share repurchase authorization as of the end of the first quarter.

    Fiscal Year 2026 Outlook

    The Company is reiterating its outlook for fiscal year 2026, as follows:

    Fiscal Year 2026 Outlook

     

    Range

    Core Nutritional business net sales

    $720 to $765 million*

    Hiya net sales

    $140 to $155 million

    Rise Wellness net sales

    $65 to $80 million

    Consolidated net sales

    $925 million to $1.0 billion

     

     

    Net earnings

    $20 million to $27 million

    Diluted EPS

    $1.11 to $1.45

    Adjusted diluted EPS(1)

    $1.95 to $2.29

    Adjusted EBITDA(2)

    $101 million to $109 million

    *Reflects an expected favorable currency exchange rate impact of approximately $19 million, or 3% on net sales and one less week of operations compared to fiscal year 2025 which was a 53-week year.

    "Consolidated first quarter operating results reflected meaningful sequential top line improvement, driven by total active customer growth in China in our Core Nutritional business and the fulfillment of Rise Wellness orders. We delivered adjusted EBITDA of $28.4 million and adjusted diluted EPS of $0.61, demonstrating that we are funding the growth of our omnichannel portfolio from a position of financial strength," said Doug Hekking, Chief Financial Officer. "Our balance sheet remains healthy with $163 million in cash, providing the flexibility to continue executing our strategic priorities. We are also making progress on our technology modernization initiative, which we are funding primarily through repurposing existing resources as well as savings from operational efficiencies, underscoring our commitment to innovation while maintaining fiscal discipline. On the strength of our first quarter results and our visibility into the growth catalysts ahead, we are reaffirming our fiscal 2026 guidance across all metrics."

    _________________________

    (1) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted Earnings Per Share. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

    (2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

    Non-GAAP Financial Measures

    This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

    Adjusted EBITDA (non-GAAP) is net earnings (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, and transaction-related expenses and integration costs for the Hiya acquisition. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.

    Adjusted diluted earnings per share (non-GAAP) is diluted earnings per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, and integration costs related to the Hiya acquisition.

    Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted earnings per share (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

    The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP") and investors should not directly compare with or infer relationship from any of the Company's operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted earnings per share. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.

    Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (non-GAAP)

    (in thousands)

     

     

     

    Quarter ended

     

     

    April 4,

    2026

     

    March 29,

    2025

    Net earnings attributable to USANA (GAAP)

     

    $

    7,515

     

     

    $

    9,402

     

    Net (loss) earnings attributable to noncontrolling interest

     

     

    (556

    )

     

     

    (112

    )

    Net earnings

     

    $

    6,959

     

     

    $

    9,290

     

     

     

     

     

     

    Adjustments:

     

     

     

     

    Income taxes

     

    $

    8,506

     

     

    $

    7,449

     

    Interest (income) expense

     

     

    (197

    )

     

     

    (312

    )

    Depreciation and amortization

     

     

    5,334

     

     

     

    5,790

     

    Amortization of intangible assets - Hiya

     

     

    4,455

     

     

     

    4,455

     

    Earnings before interest, taxes, depreciation, and amortization (EBITDA)

     

    $

    25,057

     

     

    $

    26,672

     

     

     

     

     

     

    Add EBITDA adjustments:

     

     

     

     

    Non-cash share-based compensation

     

     

    3,454

     

     

     

    2,880

     

    Transaction, integration and transition costs - Hiya

     

     

    239

     

     

     

    577

     

    Inventory step-up - Hiya

     

     

    —

     

     

     

    582

     

    Adjusted EBITDA

     

     

    28,750

     

     

     

    30,711

     

    Less: Adjusted EBITDA attributable to noncontrolling interest

     

     

    (387

    )

     

     

    (954

    )

    Adjusted EBITDA attributable to USANA

     

    $

    28,363

     

     

    $

    29,757

     

    Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (non-GAAP)

    (in thousands, except per share data)

     

     

     

    Quarter ended

     

     

    April 04,

    2026

     

    March 29,

    2025

    Net earnings attributable to USANA (GAAP)

     

    $

    7,515

     

     

    $

    9,402

     

     

     

     

     

     

    Earnings per common share - Diluted (GAAP)

     

    $

    0.41

     

     

    $

    0.49

     

    Weighted Average common shares outstanding - Diluted

     

     

    18,411

     

     

     

    19,085

     

     

     

     

     

     

    Adjustment to net earnings:

     

     

     

     

    Transaction, integration and transition costs - Hiya

     

    $

    239

     

     

    $

    577

     

    Inventory step-up - Hiya

     

     

    —

     

     

     

    582

     

    Amortization of intangible assets - Hiya

     

     

    4,455

     

     

     

    4,455

     

    Adjustments to net earnings attributable to noncontrolling interest

     

     

    (942

    )

     

     

    (1,066

    )

    Income tax effect of adjustments to net earnings

     

     

    —

     

     

     

    (4

    )

    Adjusted net earnings attributable to USANA

     

    $

    11,267

     

     

    $

    13,946

     

     

     

     

     

     

    Adjusted earnings per common share - Diluted

     

    $

    0.61

     

     

    $

    0.73

     

    Weighted average common shares outstanding - Diluted

     

     

    18,411

     

     

     

    19,085

     

    Management Commentary Document and Conference Call

    For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, May 6, 2026 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as "expect," "enhance," "drive," "anticipate," "intend," "improve," "promote," "should," "believe," "continue," "plan," "goal," "opportunity," "estimate," "predict," "may," "will," "could," and "would," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding growth for Hiya and Rise Wellness in 2026 and continued growth in the future; statements about the Company's long-term growth; and the statements under the sub-heading "Fiscal Year 2026 Outlook." Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to Hiya's ability to adapt to changes in the digital marketing environment to continue to generate customer acquisition, including changes in social media advertising algorithms; risks related to Rise Wellness' dependence on product orders from certain key retailers – specifically, if future orders from those retailers do not meet our forecasts or such retailers discontinue purchasing and selling Rise Wellness products; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict between the United States and Iran; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with our operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that Hiya and Rise Wellness disrupt the Company's overall strategic plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability to retain key personnel of Hiya and Rise Wellness; the ability to realize the benefits of the Hiya acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya's business with USANA's business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com. USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company and a 100% interest in Rise Wellness. Hiya and Rise Wellness offer a variety of clean-label health products. More information on Hiya can be found at www.hiyahealth.com. More information on Rise Wellness can be found on www.risebar.com and www.proteinpop.com.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)

     

     

    Three months ended

     

    April 4,

    2026

     

    March 29,

    2025

    Net sales

    $

    250,218

     

     

    $

    249,539

     

    Cost of sales

     

    59,436

     

     

     

    52,445

     

    Gross profit

     

    190,782

     

     

     

    197,094

     

    Operating expenses:

     

     

     

    Brand Partner incentives

     

    88,654

     

     

     

    89,985

     

    Selling, general and administrative

     

    88,254

     

     

     

    91,438

     

    Total operating expenses

     

    176,908

     

     

     

    181,423

     

    Earnings from operations

     

    13,874

     

     

     

    15,671

     

    Other income (expense):

     

     

     

    Interest income

     

    437

     

     

     

    723

     

    Interest expense

     

    (240

    )

     

     

    (411

    )

    Other, net

     

    1,394

     

     

     

    756

     

    Other income (expense), net

     

    1,591

     

     

     

    1,068

     

    Earnings before income taxes

     

    15,465

     

     

     

    16,739

     

    Income taxes

     

    8,506

     

     

     

    7,449

     

    Net earnings

     

    6,959

     

     

     

    9,290

     

    Less: Net (loss) earnings attributable to redeemable noncontrolling interest

     

    (556

    )

     

     

    (112

    )

    Net earnings attributable to USANA

    $

    7,515

     

     

    $

    9,402

     

     

     

     

     

    Earnings per common share attributable to USANA

     

     

     

    Basic

    $

    0.41

     

     

    $

    0.49

     

    Diluted

    $

    0.41

     

     

    $

    0.49

     

     

     

     

     

    Weighted average common shares outstanding

     

     

     

    Basic

     

    18,398

     

     

     

    19,049

     

    Diluted

     

    18,411

     

     

     

    19,085

     

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)

     

     

    As of

    April 4,

    2026

     

    As of

    January 3,

    2026

    ASSETS

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    162,751

     

    $

    158,380

    Trade accounts receivable (net of allowance of $141 and $137, respectively)

     

    9,657

     

     

    4,285

    Inventories

     

    96,358

     

     

    102,608

    Prepaid expenses and other current assets

     

    25,467

     

     

    23,132

    Total current assets

     

    294,233

     

     

    288,405

    Property and equipment, net

     

    94,625

     

     

    94,383

    Goodwill

     

    138,127

     

     

    137,962

    Intangible assets, net

     

    128,901

     

     

    133,151

    Deferred tax assets

     

    25,159

     

     

    27,209

    Other assets*

     

    57,921

     

     

    61,805

    Total assets

    $

    738,966

     

    $

    742,915

     

     

     

     

    LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities

     

     

     

    Accounts payable

    $

    16,230

     

    $

    17,263

    Line of credit

     

    14,000

     

     

    14,000

    Other current liabilities

     

    87,009

     

     

    97,302

    Total current liabilities

     

    117,239

     

     

    128,565

    Deferred tax liabilities

     

    5,057

     

     

    4,892

    Other long-term liabilities

     

    21,884

     

     

    23,186

     

     

     

     

    Redeemable noncontrolling interest

     

    51,236

     

     

    53,168

     

     

     

     

    Total stockholders' equity attributable to USANA

     

    543,550

     

     

    533,104

    Total liabilities, redeemable noncontrolling interest, and stockholders' equity

    $

    738,966

     

    $

    742,915

    *Includes noncurrent inventories of $3,029 and $4,799 as of 04-Apr-26 and 03-Jan-26, respectively. Total inventories were $99,387 and $107,407 as of 04-Apr-26 and 03-Jan-26, respectively.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    SALES BY REGION

    (in thousands)

    (unaudited)

     

     

    Quarter ended

     

     

     

     

     

     

     

     

     

    April 4,

    2026

     

    March 29,

    2025

     

    Change

    from

    prior

    year

     

    Percent

    change

     

    Currency

    impact on

    sales

     

    Percent

    change

    excluding

    currency

    impact

    Core Nutritional:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Asia Pacific

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Greater China

    $

    123,334

     

    49.3

    %

     

    $

    118,746

     

    47.6

    %

     

    $

    4,588

     

     

    3.9

    %

     

    $

    4,986

     

     

    (0.3

    %)

    Southeast Asia Pacific

     

    30,663

     

    12.3

    %

     

     

    35,720

     

    14.3

    %

     

     

    (5,057

    )

     

    (14.2

    %)

     

     

    1,942

     

     

    (19.6

    %)

    North Asia

     

    15,352

     

    6.1

    %

     

     

    18,941

     

    7.6

    %

     

     

    (3,589

    )

     

    (18.9

    %)

     

     

    (160

    )

     

    (18.1

    %)

    Asia Pacific total

     

    169,349

     

    67.7

    %

     

     

    173,407

     

    69.5

    %

     

     

    (4,058

    )

     

    (2.3

    %)

     

     

    6,768

     

     

    (6.2

    %)

    Americas and Europe

     

    35,050

     

    14.0

    %

     

     

    37,417

     

    15.0

    %

     

     

    (2,367

    )

     

    (6.3

    %)

     

     

    1,323

     

     

    (9.9

    %)

    Core Nutritional total

     

    204,399

     

    81.7

    %

     

     

    210,824

     

    84.5

    %

     

     

    (6,425

    )

     

    (3.0

    %)

     

     

    8,091

     

     

    (6.9

    %)

    Hiya

     

    32,150

     

    12.8

    %

     

     

    37,089

     

    14.9

    %

     

     

    (4,939

    )

     

    (13.3

    %)

     

     

    —

     

     

    (13.3

    %)

    Rise

     

    13,669

     

    5.5

    %

     

     

    1,626

     

    0.6

    %

     

     

    12,043

     

     

    740.7

    %

     

     

    —

     

     

    740.7

    %

    Consolidated total

    $

    250,218

     

    100.0

    %

     

    $

    249,539

     

    100.0

    %

     

    $

    679

     

     

    0.3

    %

     

    $

    8,091

     

     

    (3.0

    %)

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CORE NUTRITIONAL ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION

    (unaudited)

     

    Core Nutritional Active Brand Partners by Region(1)

    (unaudited)

     

     

    As of

    April 4, 2026

     

    As of

    March 29, 2025

    Asia Pacific

     

     

     

     

     

     

     

     

    Greater China

     

    62,000

     

    37.1

    %

     

    65,000

     

    35.3

    %

    Southeast Asia Pacific

     

    43,000

     

    25.7

    %

     

    48,000

     

    26.1

    %

    North Asia

     

    25,000

     

    15.0

    %

     

    33,000

     

    17.9

    %

    Asia Pacific Total

     

    130,000

     

    77.8

    %

     

    146,000

     

    79.3

    %

     

     

     

     

     

     

     

     

     

    Americas and Europe

     

    37,000

     

    22.2

    %

     

    38,000

     

    20.7

    %

     

     

    167,000

     

    100.0

    %

     

    184,000

     

    100.0

    %

    Core Nutritional Active Preferred Customers by Region(2)

    (unaudited)

     

     

    As of

    April 4, 2026

     

    As of

    March 29, 2025

    Asia Pacific

     

     

     

     

     

     

     

     

    Greater China

     

    173,000

     

    73.0

    %

     

    189,000

     

    68.7

    %

    Southeast Asia Pacific

     

    16,000

     

    6.7

    %

     

    27,000

     

    9.8

    %

    North Asia

     

    7,000

     

    3.0

    %

     

    12,000

     

    4.4

    %

    Asia Pacific Total

     

    196,000

     

    82.7

    %

     

    228,000

     

    82.9

    %

     

     

     

     

     

     

     

     

     

    Americas and Europe

     

    41,000

     

    17.3

    %

     

    47,000

     

    17.1

    %

     

     

    237,000

     

    100.0

    %

     

    275,000

     

    100.0

    %

    ______________________________

    (1)

    Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale.

    (2)

    Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    OPERATING RESULTS AS A PERCENTAGE OF NET SALES

    (unaudited)

     

     

     

    Quarter ended

     

     

    April 4, 2026

     

    March 29, 2025

     

     

    Core

    Nutritional

     

    Hiya

     

    Rise

     

    Consolidated

     

    Core

    Nutritional

     

    Hiya

     

    Rise

     

    Consolidated

    Net sales

     

    100.0%

     

    100.0%

     

    100.0%

     

    100.0%

     

    100.0%

     

    100.0%

     

    100.0%

     

    100.0%

    Cost of sales

     

    18.0%

     

    31.1%

     

    92.9%

     

    23.8%

     

    17.7%

     

    38.0%

     

    65.1%

     

    21.0%

    Gross profit

     

    82.0%

     

    68.9%

     

    7.1%

     

    76.2%

     

    82.3%

     

    62.0%

     

    34.9%

     

    79.0%

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Brand Partner incentives

     

    43.4%

     

    —%

     

    —

     

    35.4%

     

    42.7%

     

    —%

     

    —%

     

    36.1%

    Selling, general and administrative

     

    29.7%

     

    77.0%

     

    20.0%

     

    35.3%

     

    31.6%

     

    63.4%

     

    79.2%

     

    36.6%

    Total operating expenses

     

    73.1%

     

    77.0%

     

    20.0%

     

    70.7%

     

    74.3%

     

    63.4%

     

    79.2%

     

    72.7%

    Earnings (loss) from operations

     

    8.9%

     

    (8.1)%

     

    (12.9)%

     

    5.5%

     

    8.0%

     

    (1.4)%

     

    (44.3)%

     

    6.3%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Amortization of acquired intangible assets

     

    —%

     

    13.9%

     

    1.5%

     

    1.9%

     

    —%

     

    12.0%

     

    13.0%

     

    1.9%

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260505049746/en/

    Investor contact:

    Andrew Masuda

    Investor Relations

    (801) 954-7201

    investor.relations@usanainc.com

    Media contact:

    Sarah Searle

    (801) 954-7626

    media@usanainc.com

    Get the next $USNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    SEC Filings

    View All

    USANA Health Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    5/20/26 4:24:08 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by USANA Health Sciences Inc.

    10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    5/12/26 4:35:39 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    5/5/26 4:17:42 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fleming John Turman sold $43,928 worth of shares (2,450 units at $17.93), decreasing direct ownership by 37% to 4,230 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    6/1/26 4:36:41 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF PEOPLE OFFICER Jones Paul A. sold $129,106 worth of shares (6,813 units at $18.95), decreasing direct ownership by 55% to 5,561 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    5/29/26 1:39:23 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF FINANCIAL OFFICER Iiekking G Doug sold $100,513 worth of shares (5,360 units at $18.75), closing all direct ownership in the company (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    5/28/26 12:17:40 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA Earns Dual Best of State Honors for Product Innovation and Development

    USANA's CellSentials and Research and Development team honored at the awardsSALT LAKE CITY, June 4, 2026 /PRNewswire/ -- USANA, a leader in global nutrition, earned two Best of State awards in Salt Lake City, Utah, recognizing its CellSentials supplements and Research and Development team. USANA took home two Best of State medals this year in the following categories:Dietary Supplement—USANA CellSentials took home this honor for the tenth consecutive year Research and Development—USANA's R&D team won for the eighth timeTo learn more about USANA and its award-winning products, please visit USANA.com. "We are beyond honored to re

    6/4/26 6:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Kevin Guest Encourages Professionals to Prioritize Wellness During Professional Wellness Month

    USANA CEO says small daily habits can strengthen health, improve workplace culture, and help others thriveSALT LAKE CITY, June 1, 2026 /CNW/ -- As Professional Wellness Month begins in June, Kevin Guest, Chairman and CEO of USANA Health Sciences (NYSE:USNA), is encouraging professionals, leaders, and organizations to make wellness a priority both at work and at home. He says healthier habits create stronger people, stronger teams, and stronger communities. Professional Wellness Month highlights the connection between personal well-being and workplace success. Research continues

    6/1/26 7:18:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA's People-First Culture Earns Spot on USA TODAY Top Workplaces List

    SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA), a global leader in cellular nutrition, is proud to announce it has earned a spot on the prestigious 2026 USA TODAY Top Workplaces award list. The award honors organizations with 150 or more employees that have created exceptional, people-first cultures. This year, more than 40,500 organizations were invited to participate. The winners are recognized for their commitment to fostering a workplace environment that values employee listening and engagement.USANA earned its place on the list in part because

    5/7/26 7:22:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Reports First Quarter 2026 Results

    Company Continues to Make Significant Progress on Transformation to Becoming a Leading Omnichannel Health and Wellness Platform USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended April 4, 2026. Key Financial Results First Quarter 2026 vs. First Quarter 2025 Net sales of $250 million versus $250 million. Net earnings of $7.5 million versus $9.4 million. Diluted EPS of $0.41 as compared with $0.49. Adjusted diluted EPS(1) of $0.61 as compared with $0.73. Adjusted EBITDA(2) of $28.4 million versus $29.8 million. Core Nutritional Active Customers of 404,000 versus 459,000. Hiya Active Monthly Subscribers of 186

    5/5/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Schedules First Quarter 2026 Earnings Release and Conference Call

    USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2026 results will be released after the close of market on Tuesday, May 5, 2026. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, May 6, 2026 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures high-

    4/15/26 7:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care